Patents Examined by Shafiqul Haq
  • Patent number: 11940453
    Abstract: The present invention inter alia provides a method, and use thereof, of predicting CV complications such as AMI, ACS, stroke, and CV death by determining the concentrations of at least one ceramide of Group A and at least one ceramide of Group B in a biological sample and comparing those concentrations to a control. Finding a decreased concentration of at least one Group A ceramide and an increased concentration of at least one Group B ceramide indicates that the subject has an increased risk of developing one or more CV complications. Also provided are a newly identified subset of ceramide molecules, labelled versions thereof, and kits and compositions comprising the same for use in predicting and/or diagnosing CV complications.
    Type: Grant
    Filed: February 10, 2022
    Date of Patent: March 26, 2024
    Inventor: Reijo Laaksonen
  • Patent number: 11931428
    Abstract: Provided herein is a compound of formula I: and the use thereof for detecting the presence of hydrogen sulfide in cells or tissues in vitro or in vivo. The detecting may be useful, for example, in diagnosing cancer or other diseases related to imbalanced hydrogen sulfide (H2S) production such as neurodegenerative diseases.
    Type: Grant
    Filed: August 21, 2020
    Date of Patent: March 19, 2024
    Assignee: Wake Forest University Health Sciences
    Inventor: John C. Lukesh, III
  • Patent number: 11913944
    Abstract: Provided herein are compositions and methods for photoaffinity labeling of molecular targets. In particular, probes that specifically interact with cellular targets based on their affinity and are then covalently linked to the cellular target via a photoreactive group (PRG) on the probe.
    Type: Grant
    Filed: March 20, 2020
    Date of Patent: February 27, 2024
    Assignee: Promega Corporation
    Inventors: Sergiy Levin, Rachel Friedman Ohana, Robin Hurst, Thomas Kirkland, Keith Wood
  • Patent number: 11906524
    Abstract: The present subject matter provides urea biosensors as well as compositions, devices, and methods comprising such biosensors.
    Type: Grant
    Filed: November 19, 2016
    Date of Patent: February 20, 2024
    Assignee: Duke University
    Inventors: Homme W. Hellinga, Malin J. Allert
  • Patent number: 11906516
    Abstract: The present disclosure relates to a sensor for the detection of analytes, in particular for the detection of biomolecules. The sensor includes a (bio)compatible sensing layer including a polymer matrix or gel matrix, particularly a polymer gel matrix, organic nanoparticles and, optionally, one or several cell adhesion layer(s). The cell adhesion layer(s) can be varied depending on the type of cells. In the presence of the analytes, the organic nanoparticles are capable of photon up-conversion emission. The sensor further optionally includes plasmonic metal nanoparticles. The present disclosure further relates to methods of producing such a sensor and to uses of such a sensor.
    Type: Grant
    Filed: March 23, 2017
    Date of Patent: February 20, 2024
    Assignee: Sony Corporation
    Inventors: Michaela Mai, Anthony Roberts, Tzenka Miteva, Gabriele Nelles, Jan Rother
  • Patent number: 11899011
    Abstract: An assay substrate including a first component comprising a sensor molecule labeled with a quantum dot, the quantum dot immobilized to an assay substrate surface with a first linker being a bi-polar linker comprising a first binding group for specific binding of the quantum dot and a second binding group for specific binding of the assay substrate surface, the sensor molecule having a specific binding site for an organic analyte, the sensor molecule labeled with the quantum dot in a position that has no effect on the organic analyte binding the specific binding site; and a second component comprising a chemical analogue of the organic analyte, the chemical analogue labeled with a fluorescent dye, the chemical analogue linked to the quantum dot with a second linker having a length exceeding Foster radius, and the chemical analogue reversibly binding the specific binding site of the sensor molecule of the first component.
    Type: Grant
    Filed: April 27, 2023
    Date of Patent: February 13, 2024
    Assignee: QanikDX OU
    Inventors: Sergei Babitshenko, Jaak Järv, Aleksei Kuznetsov, Anton Mastitski
  • Patent number: 11891652
    Abstract: The invention relates to a method of assembling a biosensor device comprising two or more biosensor units, wherein each unit comprises one or more biosensors comprising one or more carbon nanotubes (CNTs) coated with nucleic acid and one or more sensor molecules coupled to the nucleic acid, wherein each one of the one or more sensor molecules is capable of binding to a target molecule in a sample. Each biosensor unit is capable of detecting a different target molecule in a sample, and each unit comprises one or more biosensors each capable of detecting the same target molecule. The invention further relates to biosensor devices and methods for detecting target molecules in a sample using the same.
    Type: Grant
    Filed: November 23, 2018
    Date of Patent: February 6, 2024
    Inventors: Matteo Palma, Xinzhao Xu, Pierrick Clement
  • Patent number: 11879894
    Abstract: This invention discloses bi-functional photoactivable fluorescent lipid probes for proximity labelling-based identification of membrane-associated proteins, and synthesis thereof. The photoactivable fluorescent lipid probe include a lipid moiety, a fluorophore, and a photoactivable moiety; where the fluorophore and the photoactivable moiety are covalently attached to the lipid moiety.
    Type: Grant
    Filed: June 3, 2020
    Date of Patent: January 23, 2024
    Assignee: Indian Institute of Science Education and Research
    Inventors: Gregor Jose, Thomas Pucadyil
  • Patent number: 11874280
    Abstract: Compositions comprising fluorescent or colored dyes and methods of using the same in combination with divalent metal salts to analyze samples are disclosed.
    Type: Grant
    Filed: March 8, 2019
    Date of Patent: January 16, 2024
    Assignee: Sony Group Corporation
    Inventors: Melissa Jackson, Christopher Boyce, Eriko Matsui, Michael Vanbrunt, Sharat Singh, Tracy Matray
  • Patent number: 11867705
    Abstract: Compounds and methods for use in detecting gabapentin in a sample suspected of containing gabapentin are disclosed. Gabapentin derivatives are used to produce gabapentin conjugates. A gabapentin-immunogenic carrier conjugate may be used as an immunogen for the preparation of an anti-gabapentin antibody. A gabapentin-detectable label may be used in a signal producing system in gabapentin assays.
    Type: Grant
    Filed: September 8, 2020
    Date of Patent: January 9, 2024
    Assignee: ARK Diagnostics, Inc.
    Inventors: Johnny Jose Valdez, Byung Sook Moon, Michael Kevin Helms, Alejandro A. Orozco
  • Patent number: 11860167
    Abstract: Applicants have developed an amplification system and methodology for IHC and ISH staining that utilizes “click chemistry” to covalently bind reporter molecules to tissue.
    Type: Grant
    Filed: January 28, 2022
    Date of Patent: January 2, 2024
    Assignee: Ventana Medical Systems, Inc.
    Inventors: Brian D. Kelly, Nathan W. Polaske
  • Patent number: 11860158
    Abstract: The invention relates to unmasking endotoxins in compositions so that previously present, but undetectable endotoxins are rendered detectable.
    Type: Grant
    Filed: February 22, 2019
    Date of Patent: January 2, 2024
    Inventors: Johannes Reich, Holger Grallert
  • Patent number: 11850286
    Abstract: The present invention relates to a compound comprising an alpha-end and an omega-end, the compound comprising on the alpha-end a reactive group Q1 capable of reacting with a functional group F1 present on a biomolecule and on the omega-end a target molecule, the compound further comprising a group according to formula (1) or a salt thereof: Said compound may also be referred to as a linker-conjugate. The invention also relates to a process for the preparation of a bioconjugate, the process comprising the step of reacting a reactive group Q1 of a linker-conjugate according to the invention with a functional group F1 of a biomolecule. The invention further relates to a bioconjugate obtainable by the process according to the invention.
    Type: Grant
    Filed: October 5, 2020
    Date of Patent: December 26, 2023
    Assignee: SYNAFFIX B.V.
    Inventors: Jorge Merijn Mathieu Verkade, Maria Antonia Wijdeven, Petrus Josephus Jacobus Maria Van De Sande, Sander Sebastiaan Van Berkel, Floris Louis Van Delft
  • Patent number: 11835518
    Abstract: Disclosed herein are immunoassays for detecting an anti-thyroid peroxidase antibody in a biological sample from a subject and/or diagnosing a thyroid disease in a subject. The disclosed immunoassays employ a recombinant cynomolgus monkey thyroid peroxidase (rTPO) and assess the level of anti-thyroid peroxidase antibody-induced formation or disruption of complexes comprising a solid support and the rTPO.
    Type: Grant
    Filed: April 6, 2022
    Date of Patent: December 5, 2023
    Assignee: Siemens Healthcare Diagnostics Inc.
    Inventors: Kayla Cortese, Saji Cherian, Paul D'Agostino, Gabriel Hammarquist, Aili Han, Kuldeep Jaggi, Maral Poladian, Niver Sahakian, Seema Sinha, Prakash Tewari, Haekyung Lee
  • Patent number: 11821901
    Abstract: Styryl compounds useful for preparing biological detections probes, and the use of the Styryl compounds for the detection, discrimination and quantification of biological targets.
    Type: Grant
    Filed: August 15, 2020
    Date of Patent: November 21, 2023
    Assignee: AAT Bioquest, Inc.
    Inventors: Zhenjun Diwu, Zhen Luo, Jixiang Liu, Pengfei Dong
  • Patent number: 11808770
    Abstract: Methods for in situ detecting proximity of two targets of interest featuring an antibody conjugated with a cleavable bridge component having a detectable moiety and an antibody conjugated with a non-cleavable bridge component. The bridge components each have a chemical ligation group adapted to form a covalent bond under particular conditions and when the targets are in close proximity. Following covalent bond formation, the cleavable bridge component can be cleaved from the antibody, effectively transferring the detectable moiety to the non-cleavable bridge component. Detection of the detectable moiety is indicative of the targets being in close proximity. The methods are compatible with both chromogenic and fluorogenic detection systems. The methods may be used to perform assays wherein one or more than one proximity event is detected on the same slide.
    Type: Grant
    Filed: March 4, 2020
    Date of Patent: November 7, 2023
    Assignee: Ventana Medical Systems, Inc.
    Inventors: Christopher Bieniarz, Rui Hong
  • Patent number: 11796540
    Abstract: The disclosure includes a method for determining an analyte in a sample in an interaction assay, including contacting a sample with an interaction modulator, wherein the interaction modulator is Poly-(4-styrenesulfonic acid-co-maleic acid) (PSSM), aminodextran, carboxymethyldextran, Poly-(2-acrylamido-2-methyl-1-propanesulfonic acid (PAMPS), triethylamine, triethanolamine, taurine, or dodecylsulfate. The disclosure includes a method for determining an analyte in an interaction assay, including contacting the sample with an interaction modulator, wherein the interaction modulator is an enhancer of the interaction assay at low analyte concentrations and is a retarder of the interaction assay at high analyte concentrations and wherein the interaction modulator is Poly-(4-styrenesulfonic acid-co-maleic acid) (PSSM) and/or Polyacrylic acid (PAA). The disclosure further relates to a kit having a detection agent specifically detecting an analyte and at least one interaction modulator.
    Type: Grant
    Filed: July 26, 2019
    Date of Patent: October 24, 2023
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Georg Kurz, Eloisa Lopez-Calle, Ewelina Hegel, Josef Roedl, Eva Hoess, Joerg Kaufmann, Marisa Kirchenbauer
  • Patent number: 11789029
    Abstract: A unique pipeline is employed for biomarker discovery that entailed domain antibody phage display, next generation sequencing analysis, and nanotechnology strategies to generate antibody mimetics are disclosed. Also disclosed are the temporal biomarkers of traumatic brain injury and their methods of use. In some embodiments, the temporal biomarkers are synthetic peptides comprising the HCDR3 sequences identified using the disclosed pipeline. In some aspects, the synthetic peptides have less than 30 amino acid residues and comprise a biotin scaffold that is linked to the HCDR3 sequences.
    Type: Grant
    Filed: June 19, 2020
    Date of Patent: October 17, 2023
    Assignee: Arizona Board of Regents on Behalf of Arizona State University
    Inventors: Briana Martinez, Sarah Stabenfeldt, Chris Diehnelt, Nicholas Stephanopoulos, Crystal Willingham, Amanda Witten, Kendall Lundgreen
  • Patent number: 11781955
    Abstract: This disclosure provides IR700-molecule conjugates and methods of their use to remove (e.g., separate or isolate) a target from a sample in vivo or from a subject in vitro. It is shown herein that exposure of IR700 to near infrared (NIR) light removes a portion of IR700, changing it from a hydrophilic molecule, to one that is hydrophobic, resulting in aggregation of IR700 and anything bound to it. For example, the disclosed IR700-molecule conjugates and methods provide photo-controlled ways to control the pharmacokinetics of a drug in vivo, and can be used to remove undesired agents from environmental or food samples or to isolate target molecules in a laboratory.
    Type: Grant
    Filed: September 21, 2020
    Date of Patent: October 10, 2023
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Hisataka Kobayashi, Peter Choyke, Martin John Schnermann
  • Patent number: 11774455
    Abstract: A peptide aptamer for specific recognition of arginine and its application are provided. The sequence of the peptide aptamer is shown in SEQ ID No. 1. The peptide aptamer is modified by a group that improves stability, or by a fluorescent group, an isotope and an electrochemical group that provide a detection signal, or by an affinity ligand and a mercapto. According to the computer-aided molecular docking simulation prediction, the peptide aptamer that can specifically bind to L-arginine is screened, which is verified by an isothermal titration calorimeter. The peptide aptamer has the advantages of good stability, strong binding ability, high specificity and low production cost.
    Type: Grant
    Filed: November 16, 2019
    Date of Patent: October 3, 2023
    Inventors: Zemeng Feng, Yumin He, Lei Deng, Zhong Cao, Zhongliang Xiao, Yulong Yin